Literature DB >> 9716487

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

P C Heinrich1, I Behrmann, G Müller-Newen, F Schaper, L Graeve.   

Abstract

The family of cytokines signalling through the common receptor subunit gp130 comprises interleukin (IL)-6, IL-11, leukaemia inhibitory factor, oncostatin M, ciliary neurotrophic factor and cardiotrophin-1. These so-called IL-6-type cytokines play an important role in the regulation of complex cellular processes such as gene activation, proliferation and differentiation. The current knowledge on the signal-transduction mechanisms of these cytokines from the plasma membrane to the nucleus is reviewed. In particular, we focus on the assembly of receptor complexes after ligand binding, the activation of receptor-associated kinases of the Janus family, and the recruitment and phosphorylation of transcription factors of the STAT family, which dimerize, translocate to the nucleus, and bind to enhancer elements of respective target genes leading to transcriptional activation. The important players in the signalling pathway, namely the cytokines and the receptor components, the Janus kinases Jak1, Jak2 and Tyk2, the signal transducers and activators of transcription STAT1 and STAT3 and the tyrosine phosphatase SHP2 [SH2 (Src homology 2) domain-containing tyrosine phosphatase] are introduced and their structural/functional properties are discussed. Furthermore, we review various mechanisms involved in the termination of the IL-6-type cytokine signalling, namely the action of tyrosine phosphatases, proteasome, Jak kinase inhibitors SOCS (suppressor of cytokine signalling), protein inhibitors of activated STATs (PIAS), and internalization of the cytokine receptors via gp130. Although all IL-6-type cytokines signal through the gp130/Jak/STAT pathway, the comparison of their physiological properties shows that they elicit not only similar, but also distinct, biological responses. This is reflected in the different phenotypes of IL-6-type-cytokine knock-out animals.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716487      PMCID: PMC1219691          DOI: 10.1042/bj3340297

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  222 in total

1.  Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression.

Authors:  A M Bennett; S F Hausdorff; A M O'Reilly; R M Freeman; B G Neel
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

2.  Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association.

Authors:  Z Y Peng; C A Cartwright
Journal:  Oncogene       Date:  1995-11-16       Impact factor: 9.867

3.  Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders.

Authors:  K Yoshida; T Taga; M Saito; S Suematsu; A Kumanogoh; T Tanaka; H Fujiwara; M Hirata; T Yamagami; T Nakahata; T Hirabayashi; Y Yoneda; K Tanaka; W Z Wang; C Mori; K Shiota; N Yoshida; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

4.  PDGF receptor-to-nucleus signaling of p91 (STAT1 alpha) transcription factor in rat smooth muscle cells.

Authors:  H Yamamoto; M Crow; L Cheng; E Lakatta; J Kinsella
Journal:  Exp Cell Res       Date:  1996-01-10       Impact factor: 3.905

5.  Stat1 depends on transcriptional synergy with Sp1.

Authors:  D C Look; M R Pelletier; R M Tidwell; W T Roswit; M J Holtzman
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

6.  In vitro binding of ciliary neurotrophic factor to its receptors: evidence for the formation of an IL-6-type hexameric complex.

Authors:  A De Serio; R Graziani; R Laufer; G Ciliberto; G Paonessa
Journal:  J Mol Biol       Date:  1995-12-15       Impact factor: 5.469

7.  Identification of the interleukin-6/oncostatin M response element in the rat tissue inhibitor of metalloproteinases-1 (TIMP-1) promoter.

Authors:  M Bugno; L Graeve; P Gatsios; A Koj; P C Heinrich; J Travis; T Kordula
Journal:  Nucleic Acids Res       Date:  1995-12-25       Impact factor: 16.971

8.  An acute phase response factor/NF-kappa B site downstream of the junB gene that mediates responsiveness to interleukin-6 in a murine plasmacytoma.

Authors:  R T Brown; I Z Ades; R P Nordan
Journal:  J Biol Chem       Date:  1995-12-29       Impact factor: 5.157

9.  Interaction of tyrosine-based sorting signals with clathrin-associated proteins.

Authors:  H Ohno; J Stewart; M C Fournier; H Bosshart; I Rhee; S Miyatake; T Saito; A Gallusser; T Kirchhausen; J S Bonifacino
Journal:  Science       Date:  1995-09-29       Impact factor: 47.728

10.  Differential activation of c-fos promoter elements by serum, lysophosphatidic acid, G proteins and polypeptide growth factors.

Authors:  C S Hill; R Treisman
Journal:  EMBO J       Date:  1995-10-16       Impact factor: 11.598

View more
  598 in total

1.  A single amino acid substitution (Trp(666)-->Ala) in the interbox1/2 region of the interleukin-6 signal transducer gp130 abrogates binding of JAK1, and dominantly impairs signal transduction.

Authors:  C Haan; H M Hermanns; P C Heinrich; I Behrmann
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

Review 2.  Receptor recognition by gp130 cytokines.

Authors:  J Bravo; J K Heath
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

3.  Cytoplasmic STAT proteins associate prior to activation.

Authors:  S Haan; M Kortylewski; I Behrmann; W Müller-Esterl; P C Heinrich; F Schaper
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

4.  Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation.

Authors:  Claude Haan; Peter C Heinrich; Iris Behrmann
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

Review 5.  gp130 cytokine signaling in the pituitary gland: a paradigm for cytokine-neuro-endocrine pathways.

Authors:  E Arzt
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 6.  What does Stat3 do?

Authors:  David E Levy; Chien-kuo Lee
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

7.  The role of endotoxin, TNF-alpha, and IL-6 in inducing the state of growth hormone insensitivity.

Authors:  Ping Wang; Ning Li; Jie-Shou Li; Wei-Qin Li
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

Review 8.  Role of the JAK/STAT signal transduction pathway in the regulation of gene expression in CNS.

Authors:  P Dell'Albani; R Santangelo; L Torrisi; V G Nicoletti; A M Giuffrida Stella
Journal:  Neurochem Res       Date:  2003-01       Impact factor: 3.996

9.  Cytokine G-protein signaling crosstalk in cardiomyocytes: attenuation of Jak-STAT activation by endothelin-1.

Authors:  George W Booz; Jonathan N E Day; Robert Speth; Kenneth M Baker
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

10.  JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.

Authors:  Andrea Bonetto; Tufan Aydogdu; Xiaoling Jin; Zongxiu Zhang; Rui Zhan; Leopold Puzis; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-06-05       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.